We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Project Ensuring Quality and Cooperation in the Chronic Obstructive Pulmonary Disease (COPD) Treatment (KOSMOS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00772733
First Posted: October 15, 2008
Last Update Posted: February 23, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
The purpose of this study is to ensure the quality of the COPD treatment in primary care by implementing planned follow-up visits, where the disease condition is evaluated and optimised in accordance with the national COPD recommendations. If relevant the general practitioner (GP) will refer patients to COPD rehabilitation conducted by relevant municipality rehabilitation teams. Secondarily the purpose is to improve collaboration and communication between the local hospital pulmonologist, GPs and the municipality rehabilitation team

Condition
COPD Chronic Diseases

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Project Ensuring Quality and Cooperation in the Chronic Obstructive Pulmonary Disease (COPD) Treatment

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Control visits at General practitioners [ Time Frame: 6-12 months ]
  • Lung function measured by spirometry [ Time Frame: 6-12 months ]

Secondary Outcome Measures:
  • Dyspnoea on MRC scale [ Time Frame: 6-12 months ]
  • Smoking status [ Time Frame: 6-12 months ]
  • Rehabilitation completed in the municipality rehabilitation team [ Time Frame: 6-12 months ]

Enrollment: 936
Study Start Date: October 2008
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   35 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Diagnosed patients with COPD, verified by spirometry in general practise and/or municipalities.
Criteria

Inclusion Criteria:

  • COPD diagnose, verified by spirometry
  • Having given informed consent

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00772733


Locations
Denmark
Research Site
Bjerringbro, Viborg, Denmark
Research Site
Moldrup, Viborg, Denmark
Research Site
Skals, Viborg, Denmark
Research Site
Aalborg, Denmark
Research Site
Arhus, Denmark
Research Site
Klarup, Denmark
Research Site
Orum, Denmark
Research Site
Skive, Denmark
Research Site
Spottrup, Denmark
Research Site
Stoholm, Denmark
Research Site
Viborg, Denmark
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Michael Skov Jensen, MD Region Hospital Viborg, DK
Study Chair: Tina Brandt Sorensen, MD Region Hospital Horsens, DK
Principal Investigator: Ove Grann Aalborg
  More Information

Responsible Party: Björn.E.Eriksson, MD, VP Medical, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00772733     History of Changes
Other Study ID Numbers: NIS-RDK-DUM-2007/1
First Submitted: October 14, 2008
First Posted: October 15, 2008
Last Update Posted: February 23, 2011
Last Verified: February 2011

Keywords provided by AstraZeneca:
Quality assurance
rehabilitation
chronic care model
COPD

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Chronic Disease
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes